How should baclofen be prescribed for spasticity, including dosing, titration, contraindications, monitoring, and tapering?

Baclofen for Spasticity Management

Baclofen is FDA-approved for spasticity from multiple sclerosis and spinal cord conditions, with oral dosing starting at 5 mg three times daily and titrating gradually to 40-80 mg daily maximum, while intrathecal baclofen should be reserved for severe cases refractory to oral therapy. 1

Indications and Patient Selection

Oral baclofen is indicated for:

• Spasticity from multiple sclerosis (particularly for flexor spasms, pain, clonus, and muscular rigidity) 1
• Spinal cord injuries and other spinal cord diseases 1
• Patients with reversible spasticity where treatment will aid in restoring residual function 1

Oral baclofen is NOT indicated for:

• Skeletal muscle spasm from rheumatic disorders 1
• Stroke, cerebral palsy, or Parkinson's disease (efficacy not established) 1

Note: Despite FDA labeling, stroke guidelines do consider oral baclofen for spasticity resulting in pain, poor skin hygiene, or decreased function, though it may cause significant sedation and have less impact compared to other conditions 2

Oral Baclofen Dosing and Titration

Standard titration schedule: 1

• Days 1-3: 5 mg three times daily
• Days 4-6: 10 mg three times daily
• Days 7-9: 15 mg three times daily
• Days 10-12: 20 mg three times daily
• Thereafter: Additional increases may be necessary, but maximum daily dose is 80 mg (20 mg four times daily) 1

Key dosing principles:

• Start at low doses and increase gradually until optimal effect is achieved (usually 40-80 mg daily) 1
• Use the lowest dose compatible with optimal response 1
• Some patients may require doses exceeding 80 mg daily for adequate relief, though this exceeds conventional recommendations 3
• Time-to-peak plasma levels and half-lives may be longer than previously reported, particularly at higher doses 3

Contraindications and Precautions

Absolute contraindications:

• Hypersensitivity to baclofen 1

Use with extreme caution in:

• Patients with hepatic or renal dysfunction (baclofen clearance may be impaired, leading to drug accumulation) 3
• Elderly patients (increased risk of sedation and adverse effects) 2
• Patients taking CNS depressants or opioids (increased sedation risk) 2

Monitoring considerations:

• Patients with neurogenic bladder and potential renal insufficiency may develop impaired renal clearance, causing gradual rise in blood levels over time 3
• Assessment should occur within 24 hours of any dose change 4

Common Adverse Effects

Frequently reported side effects include: 2, 5, 6

• Sedation and drowsiness (25-75% of patients)
• Dizziness
• Muscle weakness and fatigue
• Nausea
• Mental clouding
• Ataxia or lethargy

These adverse effects commonly limit the usefulness of oral baclofen and affect 25-75% of patients. 6

Critical Withdrawal Precautions

Abrupt discontinuation of baclofen is potentially life-threatening and must be avoided. 2

Withdrawal symptoms include: 2

• Visual and auditory hallucinations
• Anxiety and agitation
• Delirium
• Fever and tremors
• Tachycardia
• Seizures

For intrathecal baclofen withdrawal: 2

• High fever
• Altered mental status
• Rebound spasticity and muscle rigidity
• Can lead to rhabdomyolysis, multiorgan failure, and death

Tapering protocol:

• If benefits are not evident after a reasonable trial, withdraw slowly 1
• For long-term users, ideally wean slowly over 2 weeks 2
• Never abruptly discontinue, especially in perioperative settings—continue through day of surgery 2

Intrathecal Baclofen (ITB)

Consider intrathecal baclofen for: 2

• Chronic stroke patients (>6 months post-stroke) with severe spasticity 2
• Spasticity resulting in pain, poor skin hygiene, or decreased function 2
• Patients who experience intolerable side effects from oral baclofen 6
• Patients who fail to respond to maximum recommended oral dose 6
• Severe chronic lower extremity spasticity unmanageable by other interventions 2

ITB dosing principles: 4

• Can initiate pump fill and drug delivery intraoperatively with at least 8 hours monitoring
• Start with 500 mcg/mL concentration
• Starting daily dose should be twice the effective bolus screening dose (or equal to screening dose if prolonged response >8 hours)
• For adults: increase 5-15% every 24 hours for cerebral-origin spasticity; 10-30% every 24 hours for spinal-origin spasticity
• For children: increase 5-15% every 24 hours

Oral baclofen weaning after ITB initiation:

• Wean oral antispasmodics one drug at a time, beginning with oral baclofen after ITB begins 4

ITB management requires:

• Specialist input for perioperative planning 2
• Close monitoring for dose adjustment and pump problems 7
• Understanding of delivery system, programming, and dose effects 7

Efficacy Data

Oral baclofen:

• May reduce spasticity and pain but often without significant functional gains 2
• Responder rate may be low in stroke patients (only 3 of 29 patients in one study showed meaningful response) 8
• May cause significant sedation and have less impact on spasticity in stroke compared to other conditions 2

Intrathecal baclofen:

• Most effective means of treating diffuse abnormal spasticity of both cerebral and spinal origin 7
• Average reductions in Modified Ashworth Scale: 1.7±1.3 5
• Average reductions in Penn Spasm Frequency scores: 1.6±1.4 5
• Increased efficacy compared to oral administration 5
• Generally remains effective for years without drug tolerance 9

Alternative Considerations

If oral baclofen fails or causes intolerable side effects, consider: 2

• Tizanidine (particularly for chronic stroke patients—shown efficacy with improvement in spasticity and pain without loss of motor strength) 2
• Dantrolene (limited trial data, cited benefit of no cognitive side effects) 2
• Botulinum toxin for focal spasticity (strong recommendation for upper and lower limb) 2
• Intrathecal baclofen for refractory cases 2

Avoid benzodiazepines (including diazepam) during stroke recovery period due to possible deleterious effects on recovery and sedation. 2